Background {#Sec1}
==========

Sepsis remains the most common cause of vasodilatory shock worldwide. International consensus guidelines describe specific recommendations regarding treatment. These include the timing of important interventions comprising blood culture collection, initiation of broad-spectrum antibiotics, blood glucose targets, use of steroids, and restoration of optimal hemodynamic status \[[@CR1]\]. The mainstay of treatment with regard to restoring and maintaining optimal hemodynamic status is rapid and appropriate fluid bolus therapy (FBT) which, if insufficient, is followed by vasopressor therapy to maintain an acceptable mean arterial pressure (MAP). Despite this approach being a cornerstone of therapeutic guidelines, there is a lack of high-quality evidence demonstrating a survival benefit associated with the use of one vasopressor over another \[[@CR2]\]. Although current consensus guidelines recommend norepinephrine as the first-line vasopressor, both selection and timing of second-line therapy in refractory hypotension due to septic shock is highly variable. Indeed, in a recent survey of practice, only 14% of respondents cited a predefined dose of the first agent as the stimulus for additional therapy \[[@CR3], [@CR4]\]. Selection of the vasopressor agent is also variable and further complicated by the recent data related to a "new" vasopressor, angiotensin II, which is currently only available in the USA \[[@CR5], [@CR6]\].

Main text {#Sec2}
=========

Given that all routinely used catecholamines target the same adrenergic receptors, most clinicians are inclined to add a non-catecholamine vasopressor to treat patients with refractory hypotension due to septic shock, a decision based on three key factors: availability (a relatively rigid constraint), familiarity (often governed by previous practice), and safety profile. In our opinion, further consideration should be potential vasopressor response. Following appropriate volume resuscitation, the response to different vasopressor classes is neither uniform nor predictable. Furthermore, the responsiveness to a vasopressor may impact the outcome. Indeed, norepinephrine, recognized as the first-line vasopressor, often demonstrates a variable response which may be due to various factors which include pre-existing therapy/medications, genetics, the underlying pathophysiology of septic shock, and/or receptor responsiveness \[[@CR7]--[@CR10]\]. Both human and pre-clinical data demonstrate that septic shock impairs sympathetic modulation of the heart and vasculature \[[@CR7]\]. In fact, septic shock patients who maintain adrenergic responsiveness have better outcomes \[[@CR9]\]. Similarly, non-catecholamine vasopressors including vasopressin and angiotensin II can be affected by concomitant medications, genetics, and altered receptor responsiveness as a consequence of inflammation and sepsis \[[@CR10]--[@CR12]\]. The net effects of all of these parameters are difficult to compute at the bedside, but the key issue is whether responsiveness to a vasopressor impacts outcomes.

Non-responders to high-dose catecholamines have a dismal outcome \[[@CR13]\]. In terms of non-catecholamine agents, less than 50% of patients demonstrate a MAP response to low-dose vasopressin with this group having a significantly better survival than those that fail to respond \[[@CR14]\] (Table [1](#Tab1){ref-type="table"}). Similarly, approximately 70% of patients who receive angiotensin II have a MAP response. \[[@CR6], [@CR15]\] In a responder analysis, the ATHOS-3 study showed that a responder's chance of survival is significantly better than that of patients who fail to respond to angiotensin II \[[@CR6], [@CR15]\] (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). It follows that in patients with septic shock, the choice of vasopressor should be governed by the patient's likelihood of responding and the sensitivity to treatment. This notion is in keeping with current antimicrobial therapy paradigm wherein clinicians obtain cultures and start broad-spectrum antibiotics with the intention of de-escalating the antibiotics once the causative organism is identified.Table 1Outcomes Assessed by MAP Response to Vasopressin or Angiotensin IIVasopressin \[[@CR14]\]Angiotensin II \[[@CR6]\]Responder 45% (*n* = 426)Non-responder 55% (*n* = 512)*P* valueResponder 69.9% (*n* = 114)Non-responder 30.1% (*n* = 49)*P* valueIn-patient mortality (%)56.6%71.7%\< 0.00135%71%\< 0.0001Catecholamine dose (mcg/kg/min)0.35 ± 0.250.33 ± 0.270.180.32 ± 0.320.53 ± 0.390.0002MAP (mmHg)69 ± 1265 ± 12\< 0.00167.1 ± 5.2164.8 ± 5.020.0087Steroids (%)58.962.50.2655.357.10.8647Lactate (mmol/L)4.0 ± 3.65.4 ± 4.8\< 0.0013.43 ± 2.435.80 ± 6.010.013SOFA score13 ± 412 ± 30.4911.65 ± 2.7812.06 ± 2.990.4313Age, years62 ± 1461 ± 150.1761.7 ± 15.3263.1 ± 16.330.4278Fig. 1Survival probability by MAP response at hour 3 for patients in the ATHOS-3 trial

Conclusion {#Sec3}
==========

We propose the notion of "broad spectrum vasopressors" wherein patients with septic shock are started on multiple vasopressors with a different mechanism of action simultaneously while the vasopressor sensitivity is assessed. Vasopressor sensitivity could be assessed by sequential removal of vasopressors or developing a vasopressor sensitivity panel. Once the vasopressor sensitivities are assessed, then the vasopressors are de-escalated accordingly. However, this concept is hampered by several issues. Firstly, there is currently no bedside test that predicts the blood pressure response to catecholamines, vasopressin, or angiotensin II. Secondly, not all of these vasopressors are currently available worldwide due to either a lack of regulatory approval or cost considerations. Thirdly, there are no prospective data supporting this approach. Despite these hurdles, we feel that this is a testable hypothesis: Does time to sensitive vasopressor response improve outcomes in septic shock? We suggest this is a question worth answering and may prove an essential approach in managing these critically ill individuals.
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